Compare · HSDT vs MDT
HSDT vs MDT
Side-by-side comparison of Solana Company (HSDT) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $131.57B, about 1209.4x HSDT ($108.8M).
- MDT has been more active in the news (16 items in the past 4 weeks vs 5 for HSDT).
- MDT has more recent analyst coverage (25 ratings vs 3 for HSDT).
- Company
- Solana Company
- Medtronic plc.
- Price
- -
- -
- Market cap
- $108.8M
- $131.57B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 16
- Recent ratings
- 3
- 25
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Third Quarter 2026 Financial Results
- Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
- Solana Company Selected as a Strategic Enterprise by the Hong Kong SAR Government
- SEC Form 424B5 filed by Solana Company
- Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
- SEC Form 4 filed by Officer Tjandrasuwita Agustina Gani
- Solana Company Announces Positions and Votes on first Solana Governance Proposals
Latest MDT
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
- Medtronic to announce financial results for its second quarter of fiscal year 2027
- /C O R R E C T I O N - The Michael J. Fox Foundation for Parkinson's Research/
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation